Auxier Asset Management lifted its holdings in shares of Allergan PLC. (NYSE:AGN) by 0.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,010 shares of the company’s stock after acquiring an additional 50 shares during the period. Auxier Asset Management’s holdings in Allergan PLC. were worth $1,947,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in AGN. Howard Hughes Medical Institute acquired a new stake in shares of Allergan PLC. during the second quarter worth $103,000. Jacobi Capital Management LLC lifted its holdings in shares of Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after purchasing an additional 22 shares during the period. JNBA Financial Advisors lifted its holdings in shares of Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after purchasing an additional 12 shares during the period. Massey Quick & Co. LLC lifted its holdings in shares of Allergan PLC. by 334.8% during the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after purchasing an additional 385 shares during the period. Finally, Pacific Center for Financial Services lifted its holdings in shares of Allergan PLC. by 805.1% during the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after purchasing an additional 475 shares during the period. Institutional investors and hedge funds own 81.94% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Auxier Asset Management Increases Stake in Allergan PLC. (AGN)” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/10/20/auxier-asset-management-increases-stake-in-allergan-plc-agn.html.
Allergan PLC. (NYSE AGN) opened at 190.495 on Friday. The stock has a 50 day moving average price of $212.48 and a 200-day moving average price of $230.71. Allergan PLC. has a 12 month low of $182.80 and a 12 month high of $256.80. The stock has a market cap of $63.68 billion, a PE ratio of 5.804 and a beta of 1.15.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.35 earnings per share. On average, analysts expect that Allergan PLC. will post $16.20 EPS for the current year.
Allergan PLC. announced that its Board of Directors has authorized a stock buyback plan on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.
Several equities research analysts recently weighed in on the company. Mizuho reaffirmed a “buy” rating and set a $267.00 price target on shares of Allergan PLC. in a report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 price target on Allergan PLC. and gave the stock a “buy” rating in a report on Thursday, August 3rd. Wells Fargo & Co increased their price target on Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a report on Thursday, August 3rd. Deutsche Bank AG reaffirmed a “buy” rating and set a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Finally, BidaskClub raised Allergan PLC. from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $252.39.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.